米国市場銘柄情報

BLUE ブルーバードバイオ

銘柄追加

1.000
+0.100+11.14%

終値 05/06 16:00 ET

1.030
+0.030+3.00%

市場後 19:59 ET

1.93億時価総額-1587直近PER

ブルーバードバイオに関するコメント

ログインコメントを投稿

Trytosaveabit

10 時間前

Finally!

$ブルーバードバイオ(BLUE.US)$ Hehehe

Trytosaveabit

17 時間前

Update

$ブルーバードバイオ(BLUE.US)$ Bluebird bio Announces Completion of First Cell Collection for Lyfgenia™ Gene Therapy

Trytosaveabit

04/16 04:21

Rumor spike?

$ブルーバードバイオ(BLUE.US)$ Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"

$ブルーバードバイオ(BLUE.US)$
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.

HotShot369

03/28 00:39

I love good deals😩 my 3rd good call this week

$ブルーバードバイオ(BLUE.US)$

Trytosaveabit

03/26 22:34

$ブルーバードバイオ(BLUE.US)$ Accounting errors they say caused the restatement! So who pays for people’s losses because they went with the original numbers? Hehehe

71129854

03/26 20:42

$ブルーバードバイオ(BLUE.US)$ woof!

Trytosaveabit

03/26 19:09

Update

$ブルーバードバイオ(BLUE.US)$ bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -
- 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -
- First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -
- 62 qualified...